Endothelial dysfunction is an early step to the progression of cardiovascular diseases in diabetes. Apart from their anti-diabetic action, DPP-4 (dipeptidyl peptidase-4) inhibitors also reduce cardiovascular events in diabetic patients. However, the underlying mechanism of the beneficial effect of DPP-4 inhibitor on endothelial function is still obscure. In this study, we intervened type 1 or 2 diabetic model mice with vildagliptin for 4 weeks and measured the vascular reactivity. We found that vildagliptin improved endothelium-dependent vasodilation in diabetic mice independent of GLP-1 (glucagonlike peptide-1), but this effect was blocked by a SIRT1 (Sirtuin 1) inhibitor, Ex527. Mechanistically, vildagliptin-activated Transient Receptor Potential Channel Vanilloid 4 (TRPV4) to promote extracellular calcium uptake in endothelial cells, which activated AMPK (AMP-activated protein kinase)/SIRT1 pathway to counteract hyperglycemia-induced endothelial reactive oxygen species generation and senescence. Vildagliptin directly binds to TRPV4 by forming a hydrogen bond, which is critical to vildagliptin-evoked endothelial calcium intake. Knockout or inhibition of TRPV4 erased the beneficial role of vildagliptin. In addition, activation of SIRT1 by SRT1720 improved endothelial function independent of TRPV4 and reduced TRPV4 transcription to maintain an appropriate calcium level. In summary, our findings prove that vildagliptin protects against hyperglycemia-induced endothelial dysfunction by activating TRPV4-meditaed Ca 2+ uptake, which helps to re-understand the mechanism of DPP-4 inhibitors and expand the therapeutic scope.
Diet High in salt content have been associated with cardiovascular disease and chronic inflammation. We recently demonstrated that transient receptor potential canonical 3 (TRPC3) channels regulate myofibroblast transdifferentiation in hypertrophic scars. Here, we examined how high salt activation of TRPC3 participates in hypertrophic scarring during wound healing. In vitro, we confirmed that high salt increased the TRPC3 protein expression and the marker of myofibroblast alpha smooth muscle actin (α-SMA) in wild-type mice (WT) primary cultured dermal fibroblasts but not Trpc3−/− mice. Activation of TRPC3 by high salt elevated cytosolic Ca2+ influx and mitochondrial Ca2+ uptake in dermal fibroblasts in a TRPC3-dependent manner. High salt activation of TRPC3 enhanced mitochondrial respiratory dysfunction and excessive ROS production by inhibiting pyruvate dehydrogenase action, that activated ROS-triggered Ca2+ influx and the Rho kinase/MLC pathway in WT mice but not Trpc3−/− mice. In vivo, a persistent high-salt diet promoted myofibroblast transdifferentiation and collagen deposition in a TRPC3-dependent manner. Therefore, this study demonstrates that high salt enhances myofibroblast transdifferentiation and promotes hypertrophic scar formation through enhanced mitochondrial Ca2+ homeostasis, which activates the ROS-mediated pMLC/pMYPT1 pathway. TRPC3 deficiency antagonizes high salt diet-induced hypertrophic scarring. TRPC3 may be a novel target for hypertrophic scarring during wound healing.
Peripheral arterial disease (PAD) significantly elevates the risk of cardiovascular events in patients with type 2 diabetes (T2D). The role of transient receptor potential canonical type 6 (TRPC6) channel mediated increased calcium entry have been identified on platelets from patients with T2D. It remains unknown whether taurine benefits vascular function in patients with T2D. Diabetic patients aged 60.0 ± 8.6 years in the taurine group, N = 82; and 59.1 ± 10.4 years in the placebo group, N = 83 were randomly enrolled and received either taurine (2.4 g/day) or placebo for 12 weeks. Compared to the placebo, taurine led to a significant reduction in systolic BP, and improvement of endothelium-dependent or -independent vasodilation and pulse wave velocity after taurine 12 weeks in patients with T2D. Taurine significantly inhibited the activation of platelet calcium influx in patients with T2D. Taurine may exert beneficial the effects on blood pressure and vascular dysfunction in patients with T2D.
Renal proximal tubule plays a pivotal role in regulating sodium reabsorption and thus blood pressure. Transient receptor potential ankyrin 1 (TRPA1) has been reported to protect against renal injury by modulating mitochondrial function. We hypothesize that the activation of TRPA1 by its agonist cinnamaldehyde may mitigates high salt intake induced hypertension by inhibiting urinary sodium reabsorption through restoration of renal tubular epithelial mitochondrial function. Trpa1-deficient (Trpa1-/-) mice and wild-type (WT) mice were fed standard laboratory chow [normal diet (ND) group, 0.4% salt], standard laboratory chow with 8% salt [high-salt diet (HS) group] or standard laboratory chow with 8% salt plus 0.015% cinnamaldehyde [high-salt plus cinnamaldehyde diet (HSC) group] for six months. Urinary sodium excretion, ROS production, mitochondrial function and the expression of NHE3 and Na+/K+-ATPase of renal proximal tubules were determined. Chronic dietary cinnamaldehyde supplementation reduced tail systolic blood pressure and 24-hour ambulatory arterial pressure in HS-fed WT mice. Compared with the mice fed HS, cinnamaldehyde supplementation significantly increased urinary sodium excretion, inhibited excess ROS production and alleviated mitochondrial dysfunction of renal proximal tubules in WT mice. However, these effects of cinnamaldehyde were absent in Trpa1-/- mice. Furthermore, chronic dietary cinnamaldehyde supplementation blunted HS-induced upregulation of NHE3 and Na+/K+-ATPase in WT mice but not Trpa1-/- mice. The present study demonstrated that chronic activation of Trpa1 attenuates HS-induced hypertension by inhibiting urinary sodium reabsorption through restoring renal tubular epithelial mitochondrial function. Renal TRPA1 may be a potential target for the management of excessive dietary salt intake-associated hypertension.
Glucose homeostasis is orchestrated through the integrated actions of pancreatic insulin secretion, hepatic glucose production, and peripheral glucose utilization. However, the mechanism governing gut glucose metabolism remains incompletely characterized. We employed positron emission tomography coupled with metabolomic profiling to demonstrate that the rodent small intestine possesses a remarkable capacity to sequester and catabolize circulating fasting glucose. Notably, these effects were consistent across sexes and various physiological conditions. Mechanistic studies revealed that gut glucose assimilation during fasting is mediated by basolateral GLUT1, which is modulated through reciprocal regulation by apical angiotensin-converting enzyme 2 (ACE2) and the neutral amino acid transporter SLC6A19. Impaired gut glucose assimilation contributes to hyperglycemia in both rodent models and type 2 diabetic patients, which is associated with inhibition of SLC6A19 and disruption of ACE2/GLUT1 interaction yet ameliorated by SGLT2 inhibitors. We highlight that the small intestine harnesses glucose homeostasis through reciprocal interactions between glucose and amino acid transporters.